Canada markets closed

Theraclion SA (TCLIF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
2.28000.0000 (0.00%)
At close: 09:12AM EST
Full screen
Trade prices are not sourced from all markets
Previous Close2.2800
Open2.2800
BidN/A x N/A
AskN/A x N/A
Day's Range2.2800 - 2.2800
52 Week Range1.8500 - 2.6000
Volume2,000
Avg. Volume31
Market Cap51.914M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    Theraclion’s First Varicose Veins Treatment in Hong-Kong Opens Perspectives in Asia

    MALAKOFF, France, November 22, 2021--Regulatory News: THERACLION (Paris:ALTHE) (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing a scalable robotic platform for noninvasive echotherapy providing consistent, data driven and evidence-based patient care, announces today the completion of the first varicose veins echotherapy treatment in China. The first milestone of our study, which will open the way to Asian markets.

  • Business Wire

    Theraclion Results Show Strong Recovery, Allowing Ambitious Plans

    MALAKOFF, France, September 23, 2021--Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing a scalable robotic platform for none invasive treatment by echotherapy including varicose veins, announces today its annual results for the first 6 months of the year ended 30 June 2021 with a complete recovery from COVID period and ambitious development plans in Europe and in the US.

  • Business Wire

    FDA Approves the 1st Trial with Theraclion's Vein Therapy in the US

    MALAKOFF, France, September 21, 2021--Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE, PEA-PME eligible) (Paris:ALTHE), an innovative company specialized in echotherapy treatment (using High Intensity Focused Ultrasound or HIFU), announces FDA (Food & Drug Administration) approval for the first trial with SONOVEIN in the United States (US). After this clinical trial, a full pivotal study will be conducted for FDA review for market authorisation.